ReNewVax Ltd is a University of Liverpool spin-out company co-founded by Dr Marie Yang and Prof Aras Kadioglu. The company's slogan "Our aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines" underscores its commitment to addressing critical health challenges.
Established in 2022, ReNewVax operates in the biotechnology, health care, and life sciences sectors. Headquartered in the United Kingdom, the company has leveraged seed funding awarded by the Innovate ICURe follow-on funding and the University of Liverpool’s Enterprise Investment Fund to support its pioneering work in developing vaccines.
Though details about ReNewVax's most recent investment and investors are currently unavailable, the company's focus on combating life-threatening bacterial infections and antimicrobial resistance positions it as a promising player in the biotechnology and healthcare innovation space.